Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 2Phase NA 1Phase 3 1

Status

Completed 3Unknown 2

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Other solid neoplasm 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Advanced Pancreatic Cancer × Clear all
NCT05085548 2026-04-27

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

ProDa BioTech, LLC

Phase 1 Completed
46 enrolled
GastrointestinalOther solid neoplasm

Advanced Pancreatic Cancer

NCT04796948 2025-04-29

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
41 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

NCT04928625 2021-08-24

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1 Unknown
75 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

NCT02101580 2020-10-01

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Polaris Group

Phase 1 Completed
21 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

NCT04482257 2020-07-22

Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 1 Unknown
48 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡